Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 Oct 26



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


Original Article   Open accessopen access

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 Oct 26

DOI: 10.23736/S1824-4785.22.03468-9

Copyright © 2022 THE AUTHOR(s)

This is an open access article distributed under the terms of the CC BY-NC 4.0 license which allows users to distribute, remix, adapt and build upon the manuscript, as long as this is not done for commercial purposes, the user gives appropriate credits to the original author(s) and the source (with a link to the formal publication through the relevant DOI), provides a link to the license and indicates if changes were made.

lingua: Inglese

A retrospective study with long term follow-up of Graves’ disease patients treated with low activities of 131 Iodine

Regina NEUMANN 1, Robert THOMMAN 2, Gerhard W. GOERRES 3

1 Department of Radiology and Nuclear Medicine, GZO Spital Wetzikon, Wetzikon, Switzerland; 2 Centre for Metabolic Disease, Buergerspital Solothurn, Solothurn, Switzerland; 3 Engeried Hospital, Bern, Switzerland


BACKGROUND: Previous studies have shown that application of relatively low 131 I-Iodine activities can successfully be used to treat patients with Graves’disease (GD). We assessed treatment outcome in the long-term follow-up of our GD patients and influencing factors.
METHODS: We evaluated 521 GD patients in this retrospective clinical single-center study. In all patients we performed scintigraphy and thyroid uptake measurement after 4 h and 24 h using 10 MBq 123 I and calculated administered activity using Marinellis' formula. Treatment was done according to national regulations. Minimal routine clinical evaluation of all patients was available after 6 weeks and after 3, 6 and 12 months. Success of treatment was defined as euthyroid state or hypothyroidism 6 months after therapy.
RESULTS: We usually applied relatively low 131 I activities. 307 patients (58.9%) became hypothyroid within 21 years of follow-up. 139 patients (26.7%) became euthyroid and stayed euthyroid until the end of follow-up. We found a plateau after 7 years of initial therapy with only a few patients becoming hypothyroid after that time and identified 75 patients (14.4%) with persistent hyperthyroidism or recurrence.
CONCLUSIONS: Treatment with relatively low 131 I activities produce favourable responses as shown in previous works. We found a high proportion of patients with long-term euthyroid state. Application of low activities reduces radiation burden of patients and, depending on radiation protection legislation, may lead to shortened hospital stay and reduced costs. Therefore, we feel that application of higher activities to treat GD patients as recommended in several current guidelines should be reconsidered.

KEY WORDS: Graves' disease; Radioiodine therapy; low dose treatment; 131I-Iodine

inizio pagina